# Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

> **NCT00110994** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 101 (actual)

## Conditions studied

- Cancer
- Melanoma

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00110994
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-10
- **Final completion:** 2008-03
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2015-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110994, "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00110994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*